Komori
Chordia Therapeutics (190A) · RiskFirst stated

Risk of Liability for Damages and Product Liability Arising from Adverse Reactions

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Health Damage and Product Liability Risks Associated with PharmaceuticalsA theme 58 companies write about · 67 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2026: 6 of 19 companies on the "Worse" side.

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 58 companies compared. The sentences above are computed from all 58.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「Unexpected adverse effects may emerge with pharmaceutical products from the clinical trial stage through the post-marketing period.」

    The company listed as a standalone risk the possibility that unexpected adverse effects during clinical trials or after marketing could result in claims for damages, product liability, loss of confidence, and an impact on business performance and financial condition.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Liability for Damages and Product Liability Arising from Adverse Reactions | Chordia Therapeutics Inc. (190A) | Komori